Dyspnea Clinical Trial
Official title:
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
The goal of this monocentric double blinded cross over trial is to evaluate safety and tolerability of inhaled furosemide in patients with pulmonary diseases and dyspnea. The main question[s] it aims to answer are: - is inhaled furosemide safe and well tolerated? - is inhaled furosemide capable of dyspnea suppression and is there any additive effect of levodropropizine Participants will be given: - inhaled furosemide or placebo in double blinded cross over manner. Dyspnea severity and vital functions will be measured, adverse reactions monitored - all participants will receive levodropropizine open label. Dyspnea severity and vital functions will be measured, adverse reactions monitored
102 subjects from the pool of patients hospitalized in our pulmonary clinics will be randomized in 1:1 ratio to 2 arms in double blinded manner. Subjects in both arms will inhale first vial of study medication - furosemide 40 mg or placebo (saline). Dyspnea severity and vital functions will be measured, adverse reactions will be monitored. After an hour the subjects will inhale the second vial of study medication followed by the same procedure as earlier. Neither subjects, nor investigators will know which vial contains furosemide and which contains placebo. At last all subjects will receive levodropropizine open label and the dyspnea severity, vital signs and adverse reaction will be monitored for another hour. The measured values will be statistically evaluated a results published. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04688905 -
Diagnosing Heart Failure With Preserved Ejection Fraction in Patients With Unexplained Dyspnea (Diagnose-HFpEF)
|
||
| Completed |
NCT03679312 -
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
| Active, not recruiting |
NCT03604822 -
Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS
|
N/A | |
| Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
| Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
| Completed |
NCT02538770 -
Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization
|
N/A | |
| Completed |
NCT02248831 -
Evaluation of Cardiopulmonary Diseases by Ultrasound
|
N/A | |
| Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
| Recruiting |
NCT01655199 -
Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease
|
N/A | |
| Active, not recruiting |
NCT01440764 -
Aerosol Inhalation Treatment for Dyspnea
|
Phase 1/Phase 2 | |
| Completed |
NCT01577407 -
Non Opioid Treatment for Experimental Dyspnea
|
Phase 3 | |
| Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
| Recruiting |
NCT04327882 -
Point-of-care Ultrasound Interest in Dyspneic Emergency Department Patients: an Observational Bicentric Study
|
||
| Completed |
NCT05029986 -
Preventing Dyspnea During Speech in Older Speakers
|
N/A | |
| Not yet recruiting |
NCT04181359 -
The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
| Completed |
NCT04305639 -
The Reliability and Validity of Turkish Version of ''The Dyspnea-ALS-Scale (DALS-15)"
|
||
| Completed |
NCT04370990 -
Automated Oxygen Administration -Rethinking Interventions Alleviating Dyspnea in Patients With COPD
|
N/A | |
| Completed |
NCT04375917 -
Is Reduced Hypoxia Through a Robot Intervention, Associated With Sensory and Emotional Descriptions of Dyspnea, Anxiety, Depression, Symptom Burden and Anxiolytics
|
N/A |